Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

BACKGROUND: Targeting immune checkpoints represents an immense breakthrough in cancer therapeutics. The prognostic value of hemoglobin (Hb) has been investigated in many malignancies including non-small cell lung cancer (NSCLC). However, the prognostic impact of pretreatment Hb count for immune chec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhibo, Zhang, Fan, Yuan, Fang, Li, Ye, Ma, Junxun, Ou, Qiuxiang, Liu, Zhefeng, Yang, Bo, Wang, Lijie, Tao, Haitao, Zhang, Sujie, Li, Xiaoyan, Zhi, Xiaoyu, Ge, Xiangwei, Bao, Hua, Wu, Xue, Hu, Yi, Wang, Jinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649885/
https://www.ncbi.nlm.nih.gov/pubmed/33224276
http://dx.doi.org/10.1177/1758835920970049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649885/
https://www.ncbi.nlm.nih.gov/pubmed/33224276
http://dx.doi.org/10.1177/1758835920970049

Ejemplares similares